ClinicalTrials.Veeva

Find clinical trials for Triple Negative Breast Cancer in Portland, OR

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near Portland, OR, USA:

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

in patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received a...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Trilaciclib

Phase 2

G1 Therapeutics

Tigard, Oregon, United States and 21 other locations

immunologic activity of pembrolizumab plus chemotherapy when combined with various immunotherapy induction regimens as neoadjuvant therapy for triple...

Active, not recruiting
Breast Cancer
Breast Neoplasms
Drug: IRX 2
Drug: Pembrolizumab

Phase 2

Providence Health & Services
Providence Health & Services

Portland, Oregon, United States

doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Placebo
Drug: Atezolizumab

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Portland, Oregon, United States and 216 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Portland, Oregon, United States and 110 other locations

or ceralasertib alone in the treatment of patients with metastatic triple negative breast cancer (TNBC). Olaparib...

Enrolling
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Triple-Negative Breast Carcinoma
Other: Quality-of-Life Assessment
Drug: Ceralasertib

Phase 2

OHSU Knight Cancer Institute
OHSU Knight Cancer Institute

Portland, Oregon, United States

The goal of this study is assess the safety and tolerability of the IRX-2 regimen in patients with early stage breast cancer (ESBC)-...

Active, not recruiting
Breast Neoplasm, Male
Breast Neoplasm
Drug: Omeprazole
Drug: Cyclophosphamide

Phase 1

Providence Health & Services
Providence Health & Services

Portland, Oregon, United States

(weekly paclitaxel or capecitabine) in unresectable/metastatic triple negative breast cancer (MTNBC) patients....

Active, not recruiting
Triple Negative Breast Cancer
Drug: Paclitaxel
Drug: Capecitabine

Phase 1, Phase 2

Providence Health & Services
Providence Health & Services

Portland, Oregon, United States and 1 other location

This is a Phase II trial to assess feasibility of pembrolizumab + INBRX-106 as a chemotherapy-sparing neoadjuvant therapy. One therapeutic arm is bei...

Begins enrollment in 1 month
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: INBRX-106

Phase 2

Providence Health & Services
Providence Health & Services

Portland, Oregon, United States and 3 other locations

Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") re ...

Enrolling
Breast Cancer
Procedure: Breast Surgery
Procedure: Core Biopsy/Cryoablation

Phase 2

The University of Texas System (UT)
The University of Texas System (UT)

Portland, Oregon, United States and 3 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Paclitaxel
Drug: Gemcitabine

Phase 3

Gilead Sciences
Gilead Sciences

Portland, Oregon, United States and 506 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems